Navigation Links
High potency statins linked to better outcome following a heart attack

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins.

The study, led by the University of Dundee, also found a combination of statins and the drug ezetimibe showed no improved survival rate, although researchers caution this finding needs further testing.

"There is presently a lot of interest in ezetimibe as a potential treatment for heart patients," said Professor Chim Lang, from the Division of Cardiovascular and Diabetes Medicine at the University of Dundee Medical School.

"Ezetimibe has been shown to be very effective at lowering cholesterol but we do not know its effect on survival. The key question really is whether it is better than statins, especially high potency statins such as rosuvastatin or atorvastatin.

"What our study has showed, looking at the data from thousands of patients in the UK, is that patients who switched from normal statin treatment to high potency statins lived longer.

"Those who had ezetimibe added did not appear to have a better outcome. So for the moment the data supports the use of high potency statins, one of which, atorvastatin, is now off patent and is cheap and effective."

Results of the study have been published online in the journal Heart.

Data for the study was drawn from the UK's Clinical Practice Research Datalink. Researchers looked at the data for patients who had survived 30 days after their first heart attack, who had not received prior statin or ezetimibe therapy, and who were started on a statin within that period of their attack.

The data of 9597 patients was used. 6990 of those were treated with simvastatin, 1883 had switched to a more potent statin, and 724 were given an ezetimibe/statin combination.

Data for the group was analysed for an average 3.2 years from the start point of their first heart attack. During that time there were 1134 deaths.

The results showed that patients who switched to a high-potency statin had a 28% lower risk of death compared to those who received simvastatin. There was no observed benefit of adding ezetimibe.


Contact: Roddy Isles
University of Dundee

Related medicine news :

1. Sleep affects potency of vaccines
2. High-Potency Pot in Pregnancy May Cause Brain Damage
3. ReNew Life Launches Norwegian Gold EPA 1000 Omega, the Highest Potency EPA-only Fish Oil Supplement Sold in Health Food Stores
4. Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
5. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Prescription hCG Drops with Equal Potency to hCG Injections
6. ReNew Life, America’s #1 Probiotic Brand, Introduces a High-Potency Probiotic Uniquely Formulated for Women
7. ReNew Life, America’s #1 Probiotic Brand, Introduces a High-Potency Probiotic Uniquely Formulated for Women
8. Is There a Dark Side to High Potency Calcium? Source Naturals MBP Bone Renew Helps Consumers Avoid Potential Risks
9. Statins prevent cancer in heart transplant recipients
10. Statins May Help Prevent Enlarged Prostate: Study
11. Are Statins Less Helpful for Women?
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
(Date:12/1/2015)... ... 01, 2015 , ... It’s official: Tattoo taboo is a thing of the ... among Millennials (a whopping one in three aged 18 to 25 is inked). As ... with their ink. In fact, RealSelf , the world’s largest community for learning ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, ... fixed price per sprint agile development contract to support the National Geospatial-Intelligence Agency's ... years, provides software engineering, infrastructure, as well as operations and sustainment support to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: